'Back to the Future' as GSK Hopes to Boost Innovation

LONDON – By splitting its internal research effort into dozens of small teams, with each focusing on a particular disease or pathway, GlaxoSmithKline plc is on track to solve its productivity woes and push its return on investment in R&D to 14 percent.